At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BFRG Bullfrog AI Holdings, Inc.
Not Yet Opened 12-20 16:00:00 EST
2.09
-0.02
-0.95%
盘后2.11
+0.02+0.96%
18:55 EST
High2.25
Low2.08
Vol126.19K
Open2.12
D1 Closing2.11
Amplitude8.23%
Mkt Cap18.21M
Tradable Cap8.74M
Total Shares8.71M
T/O268.19K
T/O Rate3.02%
Tradable Shares4.18M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BRIEF-Bullfrog Ai Announces Appointment Of Chief Financial Officer
Wallachbeth Capital Announces Closing of Bullfrog AI Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
Wallachbeth Capital Announce Pricing of Bullfrog AI's Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
WallachBeth Capital Announce Pricing of Bullfrog AI's Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.